Clark Estates Inc. NY Has $4.37 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Clark Estates Inc. NY cut its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 7.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,200 shares of the biotechnology company’s stock after selling 1,000 shares during the quarter. United Therapeutics comprises about 0.8% of Clark Estates Inc. NY’s holdings, making the stock its 17th largest position. Clark Estates Inc. NY’s holdings in United Therapeutics were worth $4,372,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of UTHR. Bayesian Capital Management LP acquired a new position in shares of United Therapeutics during the 1st quarter valued at $772,000. B. Riley Wealth Advisors Inc. bought a new position in United Therapeutics in the first quarter worth approximately $219,000. California State Teachers Retirement System increased its holdings in shares of United Therapeutics by 2.1% during the first quarter. California State Teachers Retirement System now owns 74,773 shares of the biotechnology company’s stock valued at $17,177,000 after acquiring an additional 1,525 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of United Therapeutics by 2.1% during the first quarter. Tidal Investments LLC now owns 8,269 shares of the biotechnology company’s stock valued at $1,945,000 after acquiring an additional 167 shares in the last quarter. Finally, Comerica Bank raised its holdings in United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after buying an additional 9,244 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on UTHR shares. Argus boosted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen raised their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Jefferies Financial Group upped their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. LADENBURG THALM/SH SH increased their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the sale, the chief financial officer now directly owns 3,210 shares in the company, valued at $1,108,766.10. This represents a 70.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This trade represents a 85.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 127,227 shares of company stock valued at $47,398,820. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 2.3 %

Shares of UTHR opened at $377.00 on Wednesday. The stock has a 50-day moving average price of $365.54 and a 200-day moving average price of $333.04. The company has a market cap of $16.83 billion, a PE ratio of 16.56, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the firm earned $5.38 EPS. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.